In a rat model of AD, apigenin (50 mg/kg) significantly reduced the hyperphosphorylation of tau levels in the hippocampus, decreasing the expression of GSK-3β, suppressing BACE1 expression, and supporting an antiamioloidogenic activity [205]. This evidence concerns the gene MAPT and Alzheimer disease.